LHLaShonda Hall

LaShonda Hall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


LaShonda Hall has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Charles E. Rose

    National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia

    2 shared publications
  • Ebony S. Thomas

    US Centers for Disease Control and Prevention COVID‐19 Emergency Response Team, 1600 Clifton Road Atlanta GA 30329

    2 shared publications
  • Amy Martin

    Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

    1 shared publication
  • André van Zyl

    ES Corporation, 5210 Roble Grande Suite 101, San Antonio, TX 78261; US Centers for Disease Control and Prevention COVID‐19 Emergency Response Team, 1600 Clifton Road, Atlanta, GA 30329, 5210 Roble Grande Suite 101 San Antonio TX 78261

    1 shared publication
  • Christopher Conway-Washington

    Division of Infectious Diseases, Department of Medicine and the Emory Center for AIDS Research, Emory University School of Medicine, Atlanta, Georgia

    1 shared publication
  • Chuong Dinh

    Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

    1 shared publication

Latest Publications

  • Understanding COVID‐19 Vaccine Hesitancy Among K‐12 Staff, Parents, and Students: District of Columbia, February to April, 2022

    by Miguella Mark‐Carew, André van Zyl, Kathleen M. Tatti, Muhling Chong, Charles Rose, Katlynn Sifre, Daniel Jarris, William Still, Getahun Aynalem, Michael Welton, et al.

    OBJECTIVE: Despite widespread availability of COVID‐19 vaccines, millions of Americans have not received the recommended vaccine doses. In the District of Columbia (DC), COVID‐19 vaccination rates are lowest among residents who are Non‐Hispanic (NH) Black and among school‐aged children. We assessed COVID‐19 vaccine hesitancy among staff and parents of students in DC K‐12 public and public charter schools.METHODS: We conducted a telephone‐based survey from February 6 to April 16, 2022 to staff, students, and parents of students who participated in school‐based COVID‐19 screening testing. COVID‐19‐related survey items included: vaccination status, reasons for not getting vaccinated, perceived vaccine access, and trusted COVID‐19 information sources. Utilizing time‐to‐event analyses, we evaluated differences across demographic groups.RESULTS: The interview response rate was 25.8% (308/1193). Most unvaccinated participants were NH Black and ages 5 to 11 years. Median time from vaccine eligibility to uptake was 236 days for NH Black participants vs. 10 days for NH White participants. Vaccine safety was the top concern among unvaccinated participants. Government and healthcare providers were the most trusted COVID‐19 information sources.CONCLUSIONS: Differences in timing of vaccine uptake among respondents and greater vaccine hesitancy among NH Black participants compared to other racial/ethnic groups highlight a need for continued tailored outreach and communication using trusted sources to convey the importance, benefits, and safety of COVID‐19 vaccination.


  • Observed Mask Use in Kindergarten Through Grade 12 Schools in Georgia—Fall, 2021

    by LaShonda L. Hall, Ebony S. Thomas, Garrett Mahon, Charles E. Rose, Osizwe R. Harwell

    BACKGROUND: Universal masking, with additional layered prevention strategies, was an essential tool for limiting the transmission of SARS‐CoV‐2 and ensuring a safe return to in‐person learning for kindergarten through 12th grade (K‐12) students and staff. Few studies have examined mask adherence in this setting and none have described types of masks worn or locations of mask adherence. This project sought to assess mask adherence, types worn, and location of mask adherence in K‐12 settings.METHODS: This study used direct in‐person observations to measure the proportion of persons wearing masks correctly; type of masks worn; and location of mask adherence in 19 K‐12 schools in Georgia.RESULTS: A total of 16,222 observations were conducted. Among those observed, 85.2% wore masks, with 80.3% wearing the mask correctly. Persons in high school were less likely to wear masks correctly. Correct mask use was most often observed among persons wearing N95‐type masks. The prevalence of persons wearing masks correctly in transitional spaces was 5% higher than in congregate spaces.CONCLUSION: In K‐12 schools with a universal masking policy, correct mask adherence was high among individuals. Examining adherence to recommended prevention measures can provide K‐12 schools feedback to inform targeted messaging and policies during future disease outbreaks.

  • Open Access

    Short Communication: Evaluation of Antiretroviral Drug Concentrations in Minimally Invasive Specimens for Potential Development of Point-of-Care Drug Assays

    by Richard E. Haaland, Amy Martin, Melkam Mengesha, Chuong Dinh, Jeffrey Fountain, L. Davis Lupo, LaShonda Hall, Christopher Conway-Washington, Colleen F. Kelley

    Point-of-care (POC) tests for antiretroviral drugs (ARVs) could help improve individual adherence. This study sought to define the utility of urine, blood, and buccal swabs as minimally invasive specimens amenable to development of POC tests for ARVs. Urine, dried blood spots (DBS) and buccal swabs were collected from 35 HIV-negative men between 2 and 96 h after a single dose of tenofovir (TFV) alafenamide/emtricitabine (FTC)/elvitegravir (EVG)/cobicistat and darunavir (DRV). ARV concentrations were measured by high-performance liquid chromatography-mass spectrometry. High concentrations of FTC, DRV, and TFV were detectable in urine at least 24 h after dosing. FTC, DRV, and EVG remained detectable in DBS at least 24 h postdose. FTC and DRV were detectable on buccal swabs up to 2 and 24 h postdose, respectively. TFV was not detectable in DBS or buccal swabs collected between 2 and 96 h after dosing. Variable distribution of ARVs in minimally invasive specimens highlights the challenge of developing POC assays for recent ARV exposure.